Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Subtypes of Systemic Lupus Erythematosus

Lupus Nephritis 12 Incomplete lupus erythematosus 1

58 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Systemic Lupus Erythematosus

120 trials tracked for Systemic Lupus Erythematosus: 29 in phase 3 or 4 and 20 with published results. The most-cited published study has 1818 citations.

120Trials tracked
29Phase 3 & 4
0Recruiting
20With published results
Phase distribution
Phase 4 8 Phase 3 21 Phase 2 62 Phase 1 9 Other / NA 20
  1. Phase 4 Efficacy of Fish Oil in Lupus Patients Completed · 1,818 cited
  2. Phase 3 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed · 234 cited
  3. Phase 3 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed · 234 cited
  4. Phase 3 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) Completed · 162 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Completed · 111 cited
  6. Phase 3 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Completed · 95 cited
Show 44 more trials
  1. Phase 3 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed · 84 cited
  2. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 73 cited
  3. Phase 4 Belimumab Assessment of Safety in SLE Completed · 44 cited
  4. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 42 cited
  5. Phase 3 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Completed · 41 cited
  6. Phase 4 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease Completed · 38 cited
  7. Phase 4 Acthar Gel for Active Systemic Lupus Erythematosus (SLE) Completed · 38 cited
  8. Phase 4 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Completed · 33 cited
  9. Phase 3 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed · 31 cited
  10. Phase 3 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Completed · 22 cited
  11. Phase 4 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Completed · 14 cited
  12. Phase 3 Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients Completed · 11 cited
  13. Phase 4 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed · 3 cited
  14. Phase 3 A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus Completed · 1 cited
  15. Phase 4 Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) Completed
  16. Phase 3 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed
  17. Phase 3 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Completed
  18. Phase 3 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Completed
  19. Phase 3 Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Completed
  20. Phase 3 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed
  21. Phase 3 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed
  22. Phase 3 Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Completed
  23. Phase 3 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed
  24. Phase 2 A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus Completed
  25. Phase 2 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Completed
  26. Phase 2 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) Completed
  27. Phase 2 A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) Completed
  28. Phase 2 Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus Completed
  29. Phase 2 A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus Completed
  30. Phase 2 An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults Completed
  31. Phase 2 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) Completed
  32. Phase 2 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed
  33. Phase 2 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) Completed
  34. Phase 2 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus Completed
  35. Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Completed
  36. Phase 2 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Completed
  37. Phase 2 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) Completed
  38. Phase 2 Study of Anti-Malarials in Incomplete Lupus Erythematosus Completed
  39. Phase 2 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed
  40. Phase 2 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) Completed
  41. Phase 2 Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus Completed
  42. Phase 2 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed
  43. Phase 2 JBT-101 in Systemic Lupus Erythematosus (SLE) Completed
  44. Phase 2 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Completed

Showing the 50 most-cited and recently-updated of 120 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative mini-review discusses mechanisms driving coronary atherosclerosis in patients with systemic lupus erythematosus
Allergy & Immunology Sys. Review
Narrative mini-review discusses mechanisms driving coronary atherosclerosis in patients with systemic lupus erythematosus Why Lupus Can Speed Up Heart Disease, Even in Young People
This narrative mini-review synthesizes mechanistic insights regarding the link between systemic lupus erythematosus and coronary atheroscler…
Understanding how lupus harms blood vessels could help prevent heart attacks in people who don’t look high-risk.
Frontiers Apr 22, 2026
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
Allergy & Immunology Meta-analysis
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction.
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
Frontiers Apr 20, 2026
Obesity associated with reduced SLE relapse rates in Japanese registry cohort
Neurology Cohort
Obesity associated with reduced SLE relapse rates in Japanese registry cohort A Surprising Link Between Weight and Lupus Flares
This observational cohort study of 1134 patients with systemic lupus erythematosus in Japan found that obesity (BMI ≥25 kg/m2) was associate…
Being overweight or mildly obese might lower the risk of lupus relapses, challenging common beliefs about weight and autoimmune disease.
Frontiers Apr 19, 2026
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Drug Pipeline Cohort
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Frontiers Apr 19, 2026
Narrative review explores emerging therapeutic strategies targeting Th17 and Treg balance in systemic lupus erythematosus
Allergy & Immunology Sys. Review
Narrative review explores emerging therapeutic strategies targeting Th17 and Treg balance in systemic lupus erythematosus Could new drugs restore balance for lupus patients, or is the science still too early?
This narrative review examines emerging therapeutic strategies aimed at restoring the Th17 and Treg balance in patients with systemic lupus …
Doctors are exploring new drugs to restore balance between immune cells in lupus, aiming to stop attacks without shutting down the entire sy…
Frontiers Apr 16, 2026
Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients
Pediatrics Cohort
Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients Small study examines repeat kidney biopsies in children with lupus nephritis
This retrospective cohort study evaluated 19 pediatric lupus nephritis patients aged 5 to 18 years at Nanjing Children's Hospital between 20…
A small study of 19 children with lupus nephritis shows how repeat kidney biopsies track disease changes over time to guide future treatment…
Frontiers Apr 16, 2026
Case-Control Study Finds No Association Between G6PD Deficiency and Systemic Lupus Erythematosus Risk in Females
Rheumatology Case-Control
Case-Control Study Finds No Association Between G6PD Deficiency and Systemic Lupus Erythematosus Risk in Females G6PD Deficiency Does Not Raise Lupus Risk
This case-control study compared G6PD deficiency rates in 516 female systemic lupus erythematosus patients versus 491 age-matched healthy fe…
Having G6PD deficiency does not make you more likely to develop systemic lupus erythematosus.
Frontiers Apr 16, 2026
Meta-analysis links long-term glucocorticoid use and SLE duration to high osteoporosis prevalence in patients
Allergy & Immunology Meta-analysis
Meta-analysis links long-term glucocorticoid use and SLE duration to high osteoporosis prevalence in patients Lupus Patients Face Hidden Bone Loss Risk
This systematic review and meta-analysis evaluated 59 studies involving patients with systemic lupus erythematosus (SLE) to assess bone heal…
Bone loss affects 1 in 6 lupus patients, a hidden risk often overlooked due to the disease and its treatments.
Frontiers Apr 15, 2026
Case report details KFD patient developing SLE treated with immunosuppression
Pediatrics Sys. Review
Case report details KFD patient developing SLE treated with immunosuppression Your stomach hurts. You throw up. You think it is just food poisoning. But what if your immune system is fighting a hidden battle inside your lymph nodes? This story is about a rare condition that tricks doctors and changes a patient's life forever
This case report describes a single patient with Kikuchi-Fujimoto disease who subsequently developed systemic lupus erythematosus.
Severe stomach pain and vomiting from a rare immune disorder can hide a hidden battle in your lymph nodes that tricks doctors into missing t…
Frontiers Apr 15, 2026
JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases
Rheumatology Cohort
JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases Study compares heart health risks in adults with childhood-onset lupus or dermatomyositis
A single-centre longitudinal cohort study of 76 JSLE and 79 JDM adults found JSLE had higher hypertension, dyslipidaemia, and cholesterol le…
Adults with childhood lupus face higher heart risks like high blood pressure and cholesterol compared to those with juvenile dermatomyositis…
medRxiv Apr 13, 2026
Systematic review links neutrophil extracellular trap dysregulation to pregnancy complications
Diabetes & Endocrinology Sys. Review
Systematic review links neutrophil extracellular trap dysregulation to pregnancy complications Web of White Blood Cells Linked to Pregnancy Risks
A systematic review of emerging evidence indicates that dysregulation of neutrophil extracellular trap (NET) formation and clearance is stro…
A sticky web of white blood cells meant to fight germs can instead trigger serious pregnancy risks like preeclampsia and preterm birth when …
Frontiers Apr 12, 2026
Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival
Pediatrics Cohort
Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival Kids' Lungs Bleeding: Early Blood Swap Saves Lives
A retrospective cohort study of 6 pediatric patients with autoimmune diffuse alveolar hemorrhage requiring intensive care found that therape…
Early blood swaps saved six critically ill children with autoimmune lung bleeding, avoiding death in all cases treated with this urgent ther…
Frontiers Apr 12, 2026

Questions about Systemic Lupus Erythematosus

How do biologics compare to targeted drugs for treating systemic lupus erythematosus?

Biologics (e.g., anifrolumab, belimumab) and targeted drugs (e.g., telitacicept, upadacitinib) both treat SLE, but network meta-analyses show telitacicept may outperform belimumab for SRI-4 response, while anifrolumab and deucravacitinib work better for skin symptoms. Safety prof

Full answer →
How common is female sexual dysfunction in women with systemic lupus erythematosus according to recent studies?

Recent studies show that about 59% of women with systemic lupus erythematosus experience sexual dysfunction, which is significantly higher than in healthy women.

Full answer →